Notal Vision
Moshe Havilio is a Senior Algorithm Designer at Notal Vision since January 2006, where the focus has been on developing the Notal OCT analyzer, a computer vision software for the automatic detection of wet Age Related Macular Degeneration from Optical Coherence Tomography retinal imaging. Responsibilities also include research and development of algorithmic aspects for ForseeHome. Prior to this role, Moshe Havilio worked at Compugen Ltd. from May 2000 to December 2005 as an Algorithms Designer in Computational Biology, contributing to bioinformatics projects such as protein identification, statistical analysis of DNA micro-arrays, and the discovery of the human genetic transcriptional network. Moshe Havilio earned a PhD in Physics from the Technion - Israel Institute of Technology between 1994 and 1999.
This person is not in any offices
Notal Vision
Notal Vision is a patient-centric ophthalmic remote monitoring services provider extending retinal disease monitoring from the clinic to the home, providing physicians with remote monitoring services to support their patient care between office visits. With a proven approach to home-based, self-operated diagnostics, AI-enabled data analysis, and patient engagement, we help preserve patients’ vision. The Notal Vision Monitoring Center is a remote, Medicare credentialed ophthalmic provider and the epicenter of patient engagement. Led by practicing ophthalmologists and supported by certified ophthalmic professionals, the Monitoring Center offers a comprehensive nationwide age-related macular degeneration (AMD) home monitoring service for referred patients. The ForeseeHome® AMD Monitoring Program helps physicians detect the conversion to wet AMD early, leading to earlier treatment intervention and better visual outcomes. Our Home OCT pipeline technology will provide patient-initiated retinal OCT scans to support the management of patients with neovascular retinal diseases, complementing existing in-office imaging and standard of care treatments as well as emerging longer acting drugs and drug delivery systems.